This allows such cells to have enhanced glucose uptake and glycolytic metabolism even at low glucose conditions which is something wild type CRC cells are unable to accomplish, thus glucose deficiency drives the acquisition of the KRAS pathway mutation [12]. This evidence concerns the gene KRAS and colorectal carcinoma.